At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNS Marinus Pharmaceuticals
Market Closed 05-17 16:00:00 EDT
1.33
+0.03
+2.31%
盘后1.32
-0.01-0.75%
17:49 EDT
High1.38
Low1.30
Vol1.31M
Open1.31
D1 Closing1.30
Amplitude6.15%
Mkt Cap73.06M
Tradable Cap51.19M
Total Shares54.93M
T/O1.74M
T/O Rate3.39%
Tradable Shares38.49M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Buy Rating Affirmed: Marinus Pharmaceuticals’ Advancements and Long-term Patent Protection Signal Strong Prospects
Marinus Pharmaceuticals Expects That Cash, Cash Equivalents And Short-term Investments Of $113.3M As Of March 31, 2024, Inclusive Of Cost Reduction Plans, Is Expected To Provide Cash Runway Into Q1 Of 2025
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.